Literature DB >> 9697710

Parvovirus B19-induced anemia as the presenting manifestation of X-linked hyper-IgM syndrome.

K Seyama1, R Kobayashi, H Hasle, A J Apter, J C Rutledge, D Rosen, H D Ochs.   

Abstract

Parvovirus B19 (B19) can cause chronic anemia due to persistent infection in immunocompromised hosts who cannot produce neutralizing antibody necessary for clearing B19. Three patients with X-linked hyper-IgM syndrome (XHIM), who were all asymptomatic until they developed B19-induced chronic anemia at the ages of 8, 14, and 17 years, respectively, were found to have mutations of the CD40L gene, including a missense mutation (T254M), a nonsense mutation resulting in a new initiation codon and loss of the intracellular domain (R11X), and a splice site mutation (nt 309+2t-->a). Antibody responses to the T cell-dependent antigen, bacteriophage phiX174, were impaired, but neutralizing antibody titers were higher than in XHIM patients with classic phenotype. All 3 patients responded to intravenous immune globulin (IVIG) treatment. Certain mutations of the CD40L gene result in a mild XHIM phenotype that may become apparent following B19 infection in patients not on IVIG therapy and therefore not protected from B19 infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697710     DOI: 10.1086/515633

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Phenotypic heterogeneity in a family with a CD40 ligand intracellular domain mutation.

Authors:  S Kiani-Alikhan; P F K Yong; K C Gilmour; D Grosse-Kreul; E G Davies; M A A Ibrahim
Journal:  J Clin Immunol       Date:  2011-10-19       Impact factor: 8.317

2.  First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes.

Authors:  Otavio Cabral-Marques; Stefanie Klaver; Lena F Schimke; Évelyn H Ascendino; Taj Ali Khan; Paulo Vítor Soeiro Pereira; Angela Falcai; Alexander Vargas-Hernández; Leopoldo Santos-Argumedo; Liliana Bezrodnik; Ileana Moreira; Gisela Seminario; Daniela Di Giovanni; Andrea Gómez Raccio; Oscar Porras; Cristina Worm Weber; Janaíra Fernandes Ferreira; Fabiola Scancetti Tavares; Elisa de Carvalho; Claudia França Cavalcante Valente; Gisele Kuntze; Miguel Galicchio; Alejandra King; Nelson Augusto Rosário-Filho; Milena Baptistella Grota; Maria Marluce dos Santos Vilela; Regina Sumiko Watanabe Di Gesu; Simone Lima; Leiva de Souza Moura; Eduardo Talesnik; Eli Mansour; Pérsio Roxo-Junior; Juan Carlos Aldave; Ekaterine Goudouris; Fernanda Pinto-Mariz; Laura Berrón-Ruiz; Tamara Staines-Boone; Wilmer O Córdova Calderón; María del Carmen Zarate-Hernández; Anete S Grumach; Ricardo Sorensen; Anne Durandy; Troy R Torgerson; Beatriz Tavares Costa Carvalho; Francisco Espinosa-Rosales; Hans D Ochs; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2014-01-09       Impact factor: 8.317

Review 3.  Update on the hyper immunoglobulin M syndromes.

Authors:  E Graham Davies; Adrian J Thrasher
Journal:  Br J Haematol       Date:  2010-02-23       Impact factor: 6.998

Review 4.  Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.

Authors:  Xiangxue Meng; Bin Yang; Wen-Chen Suen
Journal:  Innate Immun       Date:  2017-11-13       Impact factor: 2.680

5.  X-linked Hyper IgM Syndrome Presenting as Pulmonary Alveolar Proteinosis.

Authors:  Joel Gallagher; Juan Adams; Mary Hintermeyer; Troy R Torgerson; Jesus Lopez-Guisa; Hans D Ochs; Sara Szabo; Mina Salib; James Verbsky; John Routes
Journal:  J Clin Immunol       Date:  2016-06-20       Impact factor: 8.317

Review 6.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

Review 7.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

8.  Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.

Authors:  M Teresa de la Morena; David Leonard; Troy R Torgerson; Otavio Cabral-Marques; Mary Slatter; Asghar Aghamohammadi; Sharat Chandra; Luis Murguia-Favela; Francisco A Bonilla; Maria Kanariou; Rongras Damrongwatanasuk; Caroline Y Kuo; Christopher C Dvorak; Isabelle Meyts; Karin Chen; Lisa Kobrynski; Neena Kapoor; Darko Richter; Daniela DiGiovanni; Fatima Dhalla; Evangelia Farmaki; Carsten Speckmann; Teresa Español; Anna Shcherbina; Imelda Celine Hanson; Jiri Litzman; John M Routes; Melanie Wong; Ramsay Fuleihan; Suranjith L Seneviratne; Trudy N Small; Ales Janda; Liliana Bezrodnik; Reinhard Seger; Andrea Gomez Raccio; J David M Edgar; Janet Chou; Jordan K Abbott; Joris van Montfrans; Luis Ignacio González-Granado; Nancy Bunin; Necil Kutukculer; Paul Gray; Gisela Seminario; Srdjan Pasic; Victor Aquino; Christian Wysocki; Hassan Abolhassani; Morna Dorsey; Charlotte Cunningham-Rundles; Alan P Knutsen; John Sleasman; Beatriz Tavares Costa Carvalho; Antonio Condino-Neto; Eyal Grunebaum; Helen Chapel; Hans D Ochs; Alexandra Filipovich; Mort Cowan; Andrew Gennery; Andrew Cant; Luigi D Notarangelo; Chaim M Roifman
Journal:  J Allergy Clin Immunol       Date:  2016-09-30       Impact factor: 10.793

9.  Three novel mutations reflect the variety of defects causing phenotypically diverse X-linked hyper-IgM syndrome.

Authors:  E López-Granados; R Cambronero; A Ferreira; G Fontán; M C García-Rodríguez
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 10.  Autoimmunity in hyper-IgM syndrome.

Authors:  Adriana A Jesus; Alberto J S Duarte; João B Oliveira
Journal:  J Clin Immunol       Date:  2008-02-02       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.